Western Oncolytics is focused on bringing potent vaccinia-based oncolytic immunotherapies to the clinic through a dual pipeline strategy. Our lead program, WO-12, is spearheading development while our broader VET platform serves as a robust underlying backbone for continued development of versatile cancer therapeutics.

WO Website Graphics_ Optimized Pipeline.png

Western Oncolytics owns global rights to the VET platform and individual transgene development programs.